Difficulties in Assessing the Economic Burden of Alzheimer's Disease

   Background. Age-related changes associated with the decrease in health and autonomy drastically increase the cost of medical care, maintenance and treatment. Late detection of ilnesses is the root cause of escalating the economic weight from age-related diseases, causing a surge in costs for the recovery, treatment and care of those needing outside assistance. One of the age-associated diseases is Alzheimer's disease. Alzheimer's disease is one of the many manifestations of age-related dementia, accompanied by a violation of human cognitive abilities. This cluster of diseases does not affect other systems (cardiovascular, musculoskeletal, digestive), and they can operate normally. An important effect of this disease for society is the impossibility of conducting a full-fledged work activity, as memory, attention, etc. are disturbed. That is, with absolutely normally functioning body systems, a person cannot perform the simplest operations. Another important feature is the lack of an effective way to treat this disease. The pathogenesis is so complex that today there is no method of treatment aimed at all links. Also of great importance is the timeliness of detection of this disease. Due to the fact that recently there were test systems and express diagnostics for the early detection of Alzheimer's disease, it became possible to start treatment earlier, which increased the chances of recovery and reduced treatment costs in case of diagnosing moderate and severe Alzheimer's disease gravity.

   Aim. Revealing the difficulties of assessing the economic burden of Alzheimer's Disease.

   Materials and methods. To identify the difficulties of assessing the economic burden, free sources, publications on Alzheimer's disease, data from clinical guidelines, the standard for providing medical care to elderly and senile patients with cognitive disorders, information on maximum selling prices registered and included in the State Register of Vital and Essential Drugs Prices, statistical data, compulsory health insurance tariffs.

   Results. The main problematic issues of the difficulty of assessing the economic burden of Alzheimer's disease are identified.

   Conclusion. Diseases of the nervous system are of particular importance for the health of the patient, since disorders affecting this system do not allow the patient to fully and fully fulfill their labor duties. In this regard, the development of a method for assessing the cost-effectiveness of Alzheimer's disease, as one of the most common disorders of cognitive functions, is an extremely important social task aimed at optimizing the treatment process, early detection and effective treatment aimed at recovery.

1. Приказ от 17 февраля 2022 года N 81н «Об утверждении стандарта медицинской помощи пациентам пожилого и старческого возраста при когнитивных расстройствах (диагностика и лечение)».

2. Еналиев, И. Р., & Крюченкова, Т. П. (2010). Клинико-эпидемиологические, фармакоэпидемиологические и экономические аспекты старческих деменций. Социальная и клиническая психиатрия, 20(2), 33-38.

3. Petra Marešová, Josef Dolejs, Hana Mohelska and Laura K. Bryan, “Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta-Analysis”, Current Alzheimer Research (2019) 16: 1245

4. https://www.who.int/teams/mental-health-and-substance-use/treatment-care/mental-health-gap-action-programme/evidence-centre/dementia/cholinesterase-inhibitors-and-memantine-for-treatment-of-dementia

5. Информация о предельных отпускных ценах, зарегистрированных и внесенных в Государственный Реестр цен на ЖНВЛП (по состоянию на 20. 12. 2022)

6. Приложение № 8.1 к Тарифному соглашению в сфере ОМС Московского городского фонда обязательного медицинского страхования на 2022 год от 30 декабря 2021 года.